Nanosonics Ltd (NAN)
Australian Securities Exchange · Australia · prices in AUD · close of 19 Oct 2026
Key indicators
| Last close | AUD 2.970 |
|---|---|
| 52-week range | 2.640 – 4.710 |
| Return, 1 month / 3 months | +1.7% / −2.0% |
| Return, 1 year / 3 years | −37.2% / −23.5% |
| Trend | Below its 200-day average |
| RSI (14) | 56 |
| Volatility (1 year) | 41.7% |
| Worst drawdown (1 year) | -41.7% |
| Average daily value traded | 3.15M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Nanosonics is an Australian medical device company based in Sydney that develops and supplies infection prevention equipment for healthcare settings. Its main product is the trophon system, which disinfects ultrasound probes used in hospitals, clinics and other medical facilities. The company also provides the consumable cartridges and accessories that go with the system, along with service and support for its customers. Its customers are mainly healthcare providers that need to reprocess ultrasound probes safely between patient examinations.
The shares are listed on the Australian Securities Exchange in Australia under the code NAN, and the price on this page is in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Nanosonics Ltd (NAN) trades on the Australian Securities Exchange in Australia. It last closed at AUD 2.970 on 19 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 637 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 37.2% and over the last three months it fell 2.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 51 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -11.8% | ||
| From 52-week high | -35.2% | ||
| Momentum | 44 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -2.0% | ||
| 6-month return | -17.5% | ||
| 12-month return, skipping the last month | -38.3% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.7% | ||
| Liquidity | 85 · Strong | Trades actively. | |
| Average daily value traded | 3.15M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +4.2% |
|---|---|
| 1 month | +1.7% |
| 3 months | −2.0% |
| 6 months | −17.5% |
| 1 year | −37.2% |
| 3 years | −23.5% |
| 5 years | −46.6% |
Signals
| 50-day / 200-day average | 3.003 / 3.366 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.101 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.